Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report
Jiaoquan Chen, Ziyan Chen, Xiaofeng Li, Jiajun Chen, Luoyu Zhang, Liqian Peng, Bihua Liang, Quan Chen, Runxiang Li, Huaping Li, Huilan Zhu · 2026
Read Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report by Jiaoquan Chen, Ziyan Chen, Xiaofeng Li, Jiajun Chen, Luoyu Zhang, Liqian Peng, Bihua Liang, Quan Chen, Runxiang Li, Huaping Li, Huilan Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13220819.txt.
Description
Jiaoquan Chen and colleagues report a case of chronic spontaneous urticaria controlled by stapokibart in a 2026 case report. The condition raises itchy wheals and swelling without identifiable trigger, driven by mast cells, and it had tormented the forty-four-year-old woman with hives for over a year. Antihistamines failed her, and five doses of omalizumab, the second-line antibody, failed.
She was switched to stapokibart, an antibody against the interleukin-4 receptor that quiets inflammation, given as a dose and at widening intervals over thirty-five weeks. Control came fast: by week two her weekly urticaria activity score had fallen to zero and the control score reached the adequate range. By week twenty-two the control score hit its maximum, marking complete control. Three months of follow-up brought no relapse. The authors present the case as an option when omalizumab fails, while noting cyclosporine's risks make alternatives valuable.
Catalog record
| CREATOR | Jiaoquan Chen, Ziyan Chen, Xiaofeng Li, Jiajun Chen, Luoyu Zhang, Liqian Peng, Bihua Liang, Quan Chen, Runxiang Li, Huaping Li, Huilan Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |